查看文章

ContextThe Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial showed the efficacy of adjunctive, double-bolus eptifibatide therapy in reducing ischemic complications of nonurgent coronary stent implantation at 48 hours and at 30 days.ObjectiveTo determine whether the beneficial effects of eptifibatide persist at 6 months after treatment.DesignFollow-up study of a randomized, double-blind, placebo-controlled, crossover-permitted trial conducted from June 1999 through February 2000.SettingNinety-two tertiary care centers in the United States and Canada.ParticipantsA total of 2064 patients scheduled to undergo nonurgent percutaneous coronary intervention with stent implantation.InterventionPatients were randomly assigned to receive placebo or eptifibatide (two 180-µg/kg boluses 10 minutes apart and continuous infusion of 2.0 µg/kg per minute), started immediately …